Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258


The Seattle Heart Failure Model: prediction of survival in heart failure.

Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M.

Circulation. 2006 Mar 21;113(11):1424-33. Epub 2006 Mar 13.


Improving outcomes with long-term "destination" therapy using left ventricular assist devices.

Long JW, Healy AH, Rasmusson BY, Cowley CG, Nelson KE, Kfoury AG, Clayson SE, Reid BB, Moore SA, Blank DU, Renlund DG.

J Thorac Cardiovasc Surg. 2008 Jun;135(6):1353-60; discussion 1360-1. doi: 10.1016/j.jtcvs.2006.09.124.


Prediction of mode of death in heart failure: the Seattle Heart Failure Model.

Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC.

Circulation. 2007 Jul 24;116(4):392-8. Epub 2007 Jul 9.


Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide.

May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozaffarian D, Anderson JL, Renlund DG.

Am J Cardiol. 2007 Aug 15;100(4):697-700. Epub 2007 Jun 26.


Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).

Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, Oren RM, Krueger SK, Costanzo MR, Wann LS, Levitan RG, Mancini D; REMATCH Investigators..

Circulation. 2004 Aug 24;110(8):975-81. Epub 2004 Aug 16.


Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.

Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW.

Circulation. 2007 Jul 31;116(5):497-505. Epub 2007 Jul 16.


Left ventricular assist devices as destination therapy: a new look at survival.

Park SJ, Tector A, Piccioni W, Raines E, Gelijns A, Moskowitz A, Rose E, Holman W, Furukawa S, Frazier OH, Dembitsky W.

J Thorac Cardiovasc Surg. 2005 Jan;129(1):9-17. Erratum in: J Thorac Cardiovasc Surg. 2005 Jun;129(6):1464.


A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure.

Senni M, Santilli G, Parrella P, De Maria R, Alari G, Berzuini C, Scuri M, Filippi A, Migliori M, Minetti B, Ferrazzi P, Gavazzi A.

Am J Cardiol. 2006 Oct 15;98(8):1076-82. Epub 2006 Aug 30.


Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.

John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L.

Ann Thorac Surg. 2008 Oct;86(4):1227-34; discussion 1234-5. doi: 10.1016/j.athoracsur.2008.06.030.


Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers.

Koelling TM, Joseph S, Aaronson KD.

J Heart Lung Transplant. 2004 Dec;23(12):1414-22.


The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.


Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.

Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM.

Circulation. 1997 Jun 17;95(12):2660-7.


Evaluation of risk indices in continuous-flow left ventricular assist device patients.

Schaffer JM, Allen JG, Weiss ES, Patel ND, Russell SD, Shah AS, Conte JV.

Ann Thorac Surg. 2009 Dec;88(6):1889-96. doi: 10.1016/j.athoracsur.2009.08.011.


The Munich score: a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies.

Stempfle HU, Alt A, Stief J, Siebert U.

J Heart Lung Transplant. 2008 Feb;27(2):222-8. doi: 10.1016/j.healun.2007.10.016.


Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy.

Bonde P, Ku NC, Genovese EA, Bermudez CA, Bhama JK, Ciarleglio MM, Cong X, Teuteberg JJ, Kormos RL.

Ann Thorac Surg. 2012 May;93(5):1541-7; discussion 1547-8. doi: 10.1016/j.athoracsur.2012.02.008. Epub 2012 Apr 4.


A cardiopulmonary exercise testing score for predicting outcomes in patients with heart failure.

Myers J, Arena R, Dewey F, Bensimhon D, Abella J, Hsu L, Chase P, Guazzi M, Peberdy MA.

Am Heart J. 2008 Dec;156(6):1177-83. doi: 10.1016/j.ahj.2008.07.010. Epub 2008 Sep 16.


Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.

Pietrasik G, Goldenberg I, McNitt S, Polonsky B, Moss AJ, Zareba W.

J Cardiovasc Electrophysiol. 2009 Apr;20(4):395-400. doi: 10.1111/j.1540-8167.2008.01333.x. Epub 2008 Oct 27.


Comparison of observed survival after ventricular assist device placement versus predicted survival without assist device using the Seattle heart failure model.

Pamboukian SV, Tallaj JA, Brown RN, Nielsen T, George JF, Kirklin JK, Holman WL, Levy WC.

ASAIO J. 2012 Mar-Apr;58(2):93-7. doi: 10.1097/MAT.0b013e31824450f9.


Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome.

Boriani G, Rapezzi C, Diemberger I, Gonzini L, Gorini M, Lucci D, Sinagra G, Cooke RM, Di Pasquale G, Tavazzi L, Maggioni AP.

J Eval Clin Pract. 2010 Feb;16(1):82-91. doi: 10.1111/j.1365-2753.2008.01118.x. Epub 2009 Oct 27.


Supplemental Content

Support Center